Comparative effectiveness research: The experience of the National Institute for Health and Clinical Excellence

Journal of Clinical Oncology

Volumn 30, Issue 34, 2012, Pages 4267-4274

  Sorenson, Corinna ^a   Drummond, Michael ^c   Chalkidou, Kalipso ^b  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARMUSTINE; CETUXIMAB; DASATINIB; DENOSUMAB; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEMCITABINE; IMATINIB; LENALIDOMIDE; NILOTINIB; PACLITAXEL; PANITUMUMAB; TAXANE DERIVATIVE; TEMOZOLOMIDE; TOPOTECAN; TRABECTEDIN; TRASTUZUMAB;

BONE METASTASIS; BRAIN CANCER; BREAST CANCER; CANCER THERAPY; COLORECTAL CANCER; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; GASTROINTESTINAL STROMAL TUMOR; GLIOMA; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; HEALTH CARE SYSTEM; HUMAN; LEUKEMIA; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; STOMACH CANCER; UNITED KINGDOM; UNITED STATES; UTERINE CERVIX CANCER;

COMPARATIVE EFFECTIVENESS RESEARCH; GREAT BRITAIN; HUMANS; MEDICAL ONCOLOGY; NATIONAL HEALTH PROGRAMS; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS; UNITED STATES;

EID: 84870672209     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.1974     Document Type: Review

References (47)

1. Pearson SD, Rawlins MD: Quality, innovation, and value for money: NICE and the British NHS. JAMA 294:2618-2622, 2005 (Pubitemid 41697251)
2. Harris G: British Balance benefits vs. cost to latest drugs. New York Times, December 2, 2008:A1
3. Kerr DJ, Scott M: British lessons on health care reform. N Engl J Med 261:e21, 2009
4. Liberson G: It's time for NICE. Huffington Post, June 14, 2010
5. Avorn J: Debate about funding comparative-effectiveness research. N Engl J Med 260:1927-1929, 2009
6. Iglehart JK: The political fight over comparative effectiveness research. Health Aff (Millwood) 29:1757-1760, 2010
7. Kolata G, Pollack A: The evidence gap: Costly cancer drug offers hope, but also a dilemma. New York Times, July 6, 2008 http://www.nytimes.com/2008/07/ 06/health/06avastin.html?pagewanted=all
8. Mason A, Drummond MF, Ramsey S, et al: Comparison of anticancer drug coverage decisions in the United States and United Kingdom: Does the evidence support the rhetoric? J Clin Oncol 28:3234-3238, 2010
9. Patient Protection and Affordable Care Act. Pub L 111-148, 111th Congress, March 23, 2010
10. Neumann PJ, Weinstein WC: Legislating against use of cost-effectiveness information. N Engl J Med 363:1495-1497, 2010
11. National Institute for Health and Clinical Excellence: Cancer: Guidance by topic. http://www.nice.org.uk/guidance/index.jsp?action=byTopic&o=7165
12. Rawlins M, Barnett D, Stevens A: Pharmacoeconomics: NICE's approach to decision-making. Br J Clin Pharmacol 70:346-349, 2010
13. Luce BR, Kramer JM, Goodman SN, et al: Rethinking randomized clinical trials for comparative effectiveness research: The need for transformational change. Ann Intern Med 151:203-205, 2009
14. Mullins CD, Whicher D, Reese ES, et al: Generating evidence for comparative effectiveness research using more pragmatic randomized controlled trials. Pharmacoeconomics 28:969-976, 2010
15. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/
16. Chalkidou K, Lord J, Fischer A, et al: Evidence-based decision making: When should we wait for more information? Health Aff (Millwood) 27:1642-1623, 2008
17. Chalkidou K, Hoy A, Littlejohns P: Making a decision to wait for more evidence: When the National Institute for Health and Clinical Excellence recommends a technology only in the context of research. J R Soc Med 100:453-460, 2007 (Pubitemid 350044557)
18. Centers for Medicare and Medicaid Services: Guidance for the Public, Industry, and CMS Staff: National Coverage Determinations With Data Collection As a Condition of Coverage-Coverage with Evidence Development. Baltimore, MD, Centers for Medicare and Medicaid Services, 2006
19. Tunis SR, Pearson SD: Coverage options for promising technologies: Medicare's "coverage with evidence development." Health Aff (Millwood) 25:1218-1230, 2006 (Pubitemid 44497620)
20. Major outcomes in high risk hypertensive patients randomized to angiotensis-coverting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981-2997, 2002
21. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223, 2005 (Pubitemid 41345943)
22. National Institute for Health and Clinical Excellence: Leukaemia (imatinib-intolerant chronic myeloid) dasatinib and nilotinib: Appraisal consultation document. http://www.nice.org.uk/guidance/index.jsp?action= byID&o=12029
23. National Institute for Health and Clinical Excellence: Early and locally advanced breast cancer: Diagnosis and treatment. http://www.nice.org.uk/ nicemedia/pdf/CG80NICEGuideline.pdf
24. National Institute for Health and Clinical Excellence: Tacrolimus and pimecrolimus for atopic eczema. http://www.nice.org.uk/nicemedia/pdf/ TA082guidance.pdf
25. National Institute for Health and Clinical Excellence: Diabetes (types 1 and 2): Long acting insulin analogues. http://www.nice.org.uk/nicemedia/live/ 11482/32518/32518.pdf
26. Wilensky GR: Cost-effectiveness information: Yes, it's important, but keep it separate, please! Ann Intern Med 148:967-968, 2008
27. Drummond MF, Schwartz JS, Jönsson B, et al: Key principles for improved conduct of health technology assessment for resource allocation decisions. Int J Technol Assess Health Care 24:244-258, 2008 (Pubitemid 351950160)
28. Chalkidou K, Tunis S, Lopert R, et al: Comparative effectiveness research and evidence-based health policy: Experience from four countries. Milbank Q 87:339-367, 2009 http://www.nice.org.uk/nicemedia/live/11619/34030/34030.pdf
29. National Institute for Health and Clinical Excellence: Glioma (newly diagnosed and high grade): Carmustine implants and temozolomide - Final appraisal determination. http://www.nice.org.uk/guidance/index.jsp?action= article&r=true&o=34047
30. Barham L: Single technology appraisals by NICE: Are they delivering faster guidance to the NHS? Pharmacoeconomics 26:1037-1043, 2008
31. Haycox A: Does NICE blight exist, and is so, why? Pharmacoeconomics 26:987-989, 2008
32. Milewa T: Health technology adoption and the politics of governance in the UK. Soc Sci Med 63:3102-3112, 2006
33. Abelson J, Giacomini M, Lehoux P, et al: Bringing "the public" into health technology assessment and coverage policy decisions: From principle to practice. Health Policy 82:37-50, 2007 (Pubitemid 46610527)
34. Syrett K: A technocratic fix to the "legitimacy problem"? The Blair government and health care rationing in the United Kingdom. J Health Polit Policy Law 28:715-746, 2003
35. Faden RR, Chalkidou K, Appleby J, et al: Expensive cancer drugs: A comparison between the United States and the United Kingdom. Milbank Q 87:789-819, 2009
36. Raftery J: NICE and the challenge of cancer drugs. BMJ 338:b67, 2009
37. Drummond M, Neumann P, Jönsson B, et al: Can we reliably benchmark HTA organizations? Int J Technol Assess Health Care 28:159-165, 2012
38. National Institute for Health and Clinical Excellence: Keyhole surgery to remove breast tissue to treat breast cancer. http://www.nice.org.uk/nicemedia/ live/12081/43821/43821.pdf
39. Pearson SD, Bach PB: How Medicare could use comparative effectiveness research in deciding on new coverage and reimbursement. Health Aff (Millwood) 29:1796-1804, 2010
40. de Souza JA, Ratain MJ, Fendrick AM: Value-based insurance design: Aligning incentives, benefits, and evidence in oncology. J Natl Compr Canc Netw 10:18-23, 2012
41. Drummond M, Towse A: Is it time to consider the role of patient co-payments for pharmaceuticals in Europe? Eur J Health Econ 13:1-5, 2012
42. Garber AM, Sox HC: The role of costs in comparative effectiveness research. Health Aff (Millwood) 29:1805-1811, 2010
43. Malin JL: Wrestling with the high price of cancer care: Should we control costs by individuals'ability to pay or society's willing to pay? J Clin Oncol 28:3212-3214, 2010
44. Fojo T, Grady C: How much is life worth: Cetuximab, non-small lung cancer, and the $440 billion question. J Natl Cancer Inst 101:1044-1048, 2009
45. Pear R: Health official takes parting shot at "waste." New York Times, December 4, 2011:A23
46. Garner S, Littlejohns P: Disinvestment of lowvalue clinical interventions: NICEly done? BMJ 343:d4519, 2011
47. Gray BH, Gusmano MK, Collins S: AHCPR and the Politics of Health Services Research. Health Affairs (Web Exclusive) June 25, 2003